Dolutegravir: an exciting new kid on the block

Bibliography

• Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000;97:11244-9
   PubMed Web of Science ®Google Scholar
• Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464:232-6
   PubMed Web of Science ®Google Scholar
• Alian A, Griner SL, Chiang V, et al. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci USA 2009;106:8192-7
   PubMed Web of Science ®Google Scholar
• McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 2010;85:101-18
   PubMed Web of Science ®Google Scholar
• Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat 2010;13:139-50
   PubMed Web of Science ®Google Scholar
• Metifiot M, Marchand C, Maddali K, Pommier Y. Resistance to integrase inhibitors. Viruses 2010;2:1347-66
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor in healthy volunteers. Antimicrob Agents Chemother 2010;54:254-8
   PubMed Web of Science ®Google Scholar
• Cottrell M, Hadzic T, Kashuba A. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013;52:981-94
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011;25:1737-45
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Shuguang C, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012;56(3):1627-9
   PubMed Web of Science ®Google Scholar
• Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 2010;55:365-7
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011;55:3517-21
   PubMed Web of Science ®Google Scholar
• Song I, Mark S, Borland J, et al. Dolutegravir has no effect on the pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol [abstract 535]. 20th Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2013; Atlanta
   Google Scholar
• Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011;66:1567-72
   PubMed Web of Science ®Google Scholar
• Stellbrink H-J, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013;27:1771-8
   PubMed Web of Science ®Google Scholar
• Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results – SINGLE (ING114467) [abstract H556b]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 9 – 12 September 2012; San Francisco
   Google Scholar
• Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomized, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43
   PubMed Web of Science ®Google Scholar
• Feinberg J Clotet B, Khuong MA, et al. Once–daily dolutegravir is superior to darunavir/ritonavir in antiretroviral naïve adults: 48 week results from FLAMINGO (ING114915) [abstract H-1464a]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10 – 13 September 2013; Denver
   Google Scholar
• Clotet B, Khuong MA, Antinori A, et al. Once-daily dolutegravir versus darunavir/ritonavir in antiretroviral naive adults: 48 week subgroup analyses from FLAMINGO [abstract LBPS4/6]. Program and abstracts of the 14th European AIDS Conference; 16 – 19 October 2013; Brussels, Belgium
   Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;282(9893):700-8
   Google Scholar
• Sato A, Seki T, Kobayashi M, et al. In vitro passage of drug resistant HIV- 1 against a next generation integrase inhibitor (INI), S/GSK1349572 [abstract H-932]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting; 12 – 15 September 2009; San Francisco, CA
   Google Scholar
• Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [abstract 555]. 17th Conference on Retroviruses and Opportunistic Infections; 16 – 19 February 2010; San Francisco, CA
   Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013;207:740-8
   PubMed Web of Science ®Google Scholar
• Nichols G, Lazzarin A, Maggiolo F, et al. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled [abstract TULBPE19]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30–July 3 2013; Kuala Lumpur
   Google Scholar
• Curtis L, Min S, Nichols G, et al. Once-daily dolutegravir (DTG; S/GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART)-naïve adults: 48 week results from SPRING-2 (ING113086) and SINGLE (ING114467) [abstract TUPE282]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30 – July 3 2013; Kuala Lumpur
   Google Scholar
• Fransen S, Young B, Frantzell A, et al. Control of viral replication following transmission of HIV-1 exhibiting resistance to reverse transcriptase, protease, and integrase inhibitors [abstract 56]. Antiviral Ther 2010;15(Suppl 2):A67
   Google Scholar
• Varghese V, Liu TF, Rhee SY, et al. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 2010;26:1323-6
   PubMed Web of Science ®Google Scholar
• Gutiérrez C, Hernández-Novoa B, Pérez-Elías MJ, et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials 2013;14(1):10-16
   PubMed Web of Science ®Google Scholar
• Ceccherini-Silberstein F, Malet I, D'Arrigo R, et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009;11:17-29
   PubMed Web of Science ®Google Scholar
• Vavro C, Hasan S, Madsen H, et al. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 2013;57:1379-84
   Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011;55:813-21
   PubMed Web of Science ®Google Scholar
• Quashie PK, Mesplède T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012;86:2696-705
   PubMed Web of Science ®Google Scholar
• Underwood MR, Dudas K, Horton J, et al. Analysis and characterization of treatment-emergent resistance in ART-experienced, integrase inhibitor-naive subjects with dolutegravir (DTG) vs raltegravir (RAL) in SAILING (ING111762) [abstract 21]. International Workshop on HIV &hepatitis virus drug resistance and curative strategies; 4 – 8 June 2013; Toronto, ON, Canada
   Google Scholar
• Quiñones-Mateu ME, Moore-Dudley DM, Jegede O, et al. Viral drug resistance and fitness. Adv Pharmacol 2008;56:257-96
   PubMedGoogle Scholar
• Mesplède T, Quashie PK, Osman N, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013;10:22
   PubMed Web of Science ®Google Scholar
• Vavro CL, Huang J, Underwood MR, et al. Integrase genotypic and phenotypic predictors of antiviral response to dolutegravir (DTG) in subjects with resistance to integrase inhibitors (INIs) [abstract 29]. International Workshop on HIV & hepatitis virus drug resistance and curative strategies; 4 – 8 June 2013; Toronto, ON, Canada
   Google Scholar
• Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55:4552-9
   PubMed Web of Science ®Google Scholar
• Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011;204:1811-15
   PubMed Web of Science ®Google Scholar
• Abram ME, Hluhanich RM, Goodman DD, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013;57:2654-63
   PubMed Web of Science ®Google Scholar